Integrating In Vitro Analytics for Improved Antibody-Drug Conjugate Candidate Selection

Area of Science:

• Biopharmaceutical Development
• Drug Discovery and Design
• Analytical Chemistry

Background:

• Antibody-drug conjugate (ADC) development faces challenges in conjugation chemistry, linker stability, and analytical controls.
• Early screening and characterization of ADC candidates require advanced analytical methods, including plasma stability assays and enzymatic studies.
• Integrating in vitro assays with data analysis software is crucial for assessing structure-activity relationships and identifying stable compounds.

Purpose of the Study:

• To examine how combined analytical and computational approaches enhance ADC candidate selection.
• To provide insights into the metabolic fate and stability risks of ADCs.
• To demonstrate the predictive power of early-stage analytical studies for in vivo performance.

Main Methods:

• Utilizing combined analytical and computational approaches for ADC candidate assessment.
• Performing in vitro plasma stability assays and enzymatic studies.
• Employing data analysis software for visualization and assessment of structure-activity relationships.

Main Results:

• Demonstrated correlation between in vitro stability profiles and in vivo pharmacokinetic (PK) data.
• Showcased the predictive power of early-stage analytical studies in ADC development.
• Enabled faster, data-informed decision-making through software-driven analysis, streamlining candidate prioritization.

Conclusions:

• Integrated in vitro analytics and computational tools are critical for efficient ADC development.
• These integrated approaches support the selection of candidates with high clinical success potential.
• Facilitates an accelerated and more effective path from discovery to clinical application for ADCs.